Welcome to visit hoepage of ISOSDD2008



	Co-organizors :	南京人事局

Welcome to International Symposium on Organic Synthesis and Drug Development 2008

Keynote Speaker

(Alphabetically)

Aharon Jehuda Ciechanover was Nobel Winner in 2004. He was born in Haifa, Israel, he received his Master of Science in 1971 and his M.D. in 1974 from the Hadassah Medical School of the Hebrew University in Jerusalem. He received his doctorate in medicine in 1982 from the Technion (Israel Institute of Technology), in Haifa. He is currently a Professor in the Unit of Biochemistry and Director of the Rappaport Family Institute for Research in Medical Sciences at the Technion.

Ferenc Avraham Hershko was Nobel Winner in 2004. He was born in 1937, in Karcag, Hungary. He did his graduate work in 1967-69 at the Hadassah Medical School of the Hebrew University in Jerusalem, receiving a Ph. D. degree in 1969.In 1969-72, Hershko was a postdoctoral fellow at the University of California, San Francisco. He is a Distinguished Professor at the Unit of Biochemistry, the Rappaport Faculty of Medicine at the Technion (Israel Institute of Technology) in Haifa, Israel.

Karl Barry Sharpless was Nobel Winner in 2001. He was born in Philadelphia in April 28, 1941. He began his studies in Dartmouth College and earned his PhD from Stanford University in 1963. He continued post-doctoral work at Stanford University and Harvard University. Sharpless became professor at the Massachusetts Institute of Technology, Stanford University, and the Scripps Research Institute, where he currently holds the W. M. Keck professorship in chemistry.
　

Confirmed Plenary Speakers

(Alphabetically)

Burgess Kevin

Texas A&M University

USA

Libraries of Bivalent Peptidomimetics for Mimicking or Disrupting Protein-Protein Interactions

Chen Li

Chief Scientific Officer, VP, Roche-China

Regulation of Signals through Protein-Protein Interaction: 15 years and counting

Futran Mauricio

Vice President of Process Research & Development, Bristol-Myers Squibb

Knowledge Creation in Pharmaceutical Process Development in the Context of Global Partnerships

Imwinkelried Rene

Vice President of Chemical and Physical Sciences, Schering-Plough, USA

TBA

Lin Guo-Qiang

Shanghai Institute of Org.Chem, CAS and NSFC, China

New Synthetic Methodologies and Their Utilities in the Synthesis of Bio-active Products

Lipshutz Bruce

University of California, Santa Barbara, USA
Green Chemistry Using "Designer" Surfactants. Just Add Water

Lu Xiyan

Shanghai Institute of Organic Chemistry, CAS, China

Paladium(II) catalyzed addition of arylboronic acids to carbon-heteroatom multiple bonds. An enantioselective, catalytic Grignard type reaction

Portoghese Philip S.

University of Minnesota, USA

Ligands that activate heterodimeric opioid receptors: functional and clinical relevance

Schiller Peter W.

Clinical Research Institute of Montreal, Canada

Use of Novel Amino Acid Analogues in the Development of Peptides as Drugs or Pharmacological Tools

Scypinski Stephen VP of Bristol-Myers Squibb Company Overview of the Drug Development Process: Assuring Product Quality and Efficacy

Volante Ralph P

Vice President of Process Research, Merck

TBA

Invited Speakers

Confirmed Invited Speakers

Part A： Organic Synthesis

Part B： Process Chemistry

Session 1: Organic Chemistry and Process Chemistry

Session 2: Chemistry Application in Pharmaceutical Industry

Session 3: Outsourcing in Chemistry and Drug Development

Session 4: Drug Development Process

Part C：Medicinal Chemistry

Session 1: General Medicinal Chemistry

Session 2: Medicinal Chemistry Approaches to tackling Cardiovascular disease

Session 3: Medicinal Chemistry Approaches to tackling inflammation disease

Session 4.: Medicinal Chemistry Approaches to Tackling Oncology Disease

Session 5 : Medicinal Chemistry Approaches to Tackling Metabolic Disease

Part A: Organic synthesis

Bogyo Matthew	Stanford Univ.	Small molecule activity based probes for diagnostic imaging and drug discovery applications
Chen Wanzhi	Department of Chemsitry Zhejiang University	Highly Efficient Catalysts Supported by Multidentate N-Heterocyclic Carbenes for C-C Coupling Reactions
Debrabander Jef K.	Univ. of Texas Southwestern Medical Center	Natural Products: An Inspirational platform for New Discoveries
Ding Kuiling	SIOC, CAS	Development of highly efficient chiral catalysts for asymmetric reactions: practical synthesis of chiral drug intermediates
Franzen Robert	Tampere University of Technology, Department of Chemistry and Bioengineering	Recent advances in the Suzuki cross-coupling reaction of different organoboron derivatives
Huang Feihe	Zhejiang Univ.	Threaded structures based on crown ether derivative hosts
Jiang Biao	SIOC, CAS	Synthesis of Chiral Gossypol and Their Dericatives and Evaluation of Their Anticancer Activity
Liu Lei	Tsinghua Univ.	TBA
Lutz F. Tietze	Institut für Organische und Biomolekulare Chemie, Universität Göttingen.	New Approaches for a Selective Treatment of Cancer Based on Prodrugs and Monoclonal Antibody-Enzyme Conjugates
Ma Dawei	SIOC, CAS	TBA
Shaw Robert	Texas Tech University, USA	Antibiotic Resistance in Bacteria: Novel Metalloenzyme Inhibitors
Shi Zhangjie	Peking Univ.	Transition-Metal Catalyzed C-H Activation
Snyder Scott	Columbia University, USA	Achieving Synthetic Control When Nature Abandons Selectivity
Wang Meixiang	Insitute of Chemsitry, CAS	TBA
Xi Zhenfeng	Peking Univ.	Synthesis of Multiply Substituted Pyrrolopyridiens, Pyridines and Pyrroles
Yudin Andrei	University of Toronto	Protecting Group-Free Synthesis of Complex Amines
Zhang Liming	Department of Chemistry, University of Nevada, Reno	Au-Catalyzed Cycloaddition Reactions
Zhu Chengjian	Nanjing Univ.	TBA

Part B: Process Organic Chemistry

Bhongle Nandu	Sepracor	TBA
Colacot Thomas	Johnson Matthey Catalyst	Highly Active, Air-Stable Pd Catalysts for Challenging Cross-Coupling Reactions
Discordia Robert	Bristol-Myers Squibb Company	The Process Development of an MMP Inhibitor: Development and Execution of a Crystallization Induced Dynamic Resolution
Guo Paul (Peng)	President, AstaTech, Inc (USA),	Process Technology Commercialization: From Target to Technology Development
Houpis Yannis	Johnson and Johnson PRD	Carboxylate Directed Pd-Catalyzed Cross Coupling Reactions in the Selective Synthesis of tri-Substituted Aromatics
Hong Yaping	Princeton GlobalSynthesis LLC	Introduction of Chemical Process R/D : Trends and Challenges
Huang Jason	Bristol-Myers Squibb Company	Analytical Role in Pharmaceutical Development and GMP Compliance
Liang Leon	Bristol-Myers Squibb Company	TBA
Lu Zhi-Hui	Boehringer-Ingelheim Pharmaceuticals	Practical Synthesis Of 2,3-Disubstituted And Polycyclic Indoles
Ruan Joan	Bristol-Myers Squibb Company	Forced Degradation Strategy
Wang Jianji	Bristol-Myers Squibb Company	Pharmaceutical Process Research and Development
Yu Jurong	Nanjing Pharma.	My experience of doing Process R&D in China: the Story in Nanjing
Salvino Joseph M.	Director, Hit to Lead Chemistry, Cephalon, Inc.	Practical Approaches toward Lead Finding and Lead Optimization Library Synthesis
Shi Xiongwei	United Pharmatech	Sundia's Strategies and Steps towards Meeting Client's Requirement for Outsourcing Services
Zhou Maotang	VP of R&D, Chiral Quest (China)	Advances in Asymmetric Hydrogenation: From Innovative Ligands to Commercial Manufacture

Part C: Medicinal Chemistry

Cheng Jiefei	Otsuka Maryland Medicinal Laboratories Inc, USA	TheYin andYang of theFattyAcid Oxidation Modulation
Chen Li	Hoffmann-La Roche, USA	Discovery of VLA4 Antagonists for the Treatment of Autoimmune Diseases
Cherney Robert J.	Bristol-MyersSquibb, Pharmaceutical Research Institute, USA	Discovery of Potent CCR2 Antagonists
Deng Jianghe	GlaxoSmithKline. Co	Encoded Library Technology: A New Methodology for Lead Discovery
Ge Min	CSO, Acesys Pharmatech	Medicinal Chemistry Outsourcing in Nanjing
He Yun	Medical Chemistry Department，Roche R&D Center (China) Ltd	TBA
Henry Jim	Eli Lilly and Company, USA	Type II Kinase Inhibitors for the Treatment of Cancer
Jadhav Prabhakar	Eli Lilly & Company, USA	Orally bioavailable, nonsteroidal MR antagonist LY2180176 for the treament of hypertension
Kang Jiesheng	Sanofi Aventis, New Jercy, USA	HERG and the LQT Syndrome: Background, Regulations & Non-Clinical Strategy
Li Qun	Chief Scientific Officer, Egret Pharma, Shanghai, China	Design and Synthesis of Orally Bioavailable Akt Kinase (PKB) Inhibitors as Anticancer Agents
Liu Hong	The Novartis Research Foundation, San Diego, USA	Structure Based Design and Synthesis of Noncovalent Inhibitors of Cathepsin S and Their Applications in Treating Neuropathic Pain
Long Ya-Qiu	Shanghai Institute of Materia Medica Chinese Academy of Sciences	1,6-naphthyridine-7-carboxamide Templated Active Compounds: Switching From hiv-1 Integrase Inhibitors to Anti-tumor Agents
Pinto Donald	Bristol-Myers Squibb Company, Princeton, NJ 08543, USA	A Next Generation Oral Anticoagulant: The Discovery of Apixaban, a Potent, Selective and Orally Bioavailable Factor Xa Inhibitor
Procter Martin	Prosidion, UK	Design and Synthesis of Orally Bioavailable Glucokinase Activators
Qian Shawn	Associate Director, Meidcinal Chemistry, Cytokinetics, Inc	Discovery of Mitotic Kinesin Inhibitors as Novel Anticancer Agents
Shao Feng	Pepper Hamilton LLP Philadelphia, PA, USA	Navigation Through Patentability and Freedom to Operate - An Introduction to the U.S. Patent Law
Shih Joe	Eli Lilly and Company, USA	The Evolution of Lilly Oncology: From Cytotoxic Agents (Discovery and Development of ALIMTAÒ) to Kinase Inhibitors
Wang Yonghui	GlaxoSmithKline	7TM Receptor Antagonists: Lead Discovery Strategy and Case Studies
Wei Xudong	Boehringer-Ingelheim Pharmaceuticals	Practical Large Scale Synthesis of Macrocyclic HCV Protease Inhibitors
Xing Bengang	School of Physical & Mathematical Sciences Nanyang Technological University	TBA
Xu Weizheng (William)	MGI Pharmaceutical, USA	Design, Synthesis and Biological Evaluation of PARP Inhibitors as Chemosensitizers
Xu Yaohua	Novartis AG	Serotonin Antagonist And Its Application In Smoking Cessation and Anti-depression
Yao Wenqing	Incyte Corporation, USA	Discovery of Potent and Selective 11ßHSD1 Inhibitors: Scaffold Hopping Approach for Novel Lead Generation Based on Medchem Intuition
Yao Yiming	EnzMed (nanjing) Co., Ltd	Enzymatic synthesis in pharmaceutical development
Zhang Frank	CEO, Genscript Corporation	Accelerate your drug discovery by outsourcing your biology
Zhao Gang	Abbott, USA	AMPK Activators
Zhou Maotang	VP of R&D, Chiral Quest (China)	Advances in Asymmetric Hydrogenation: From Innovative Ligands to Commercial Manufacture
Zhu Guidong	Abbott Laboratories	ABT-888 and Back Up, Orally Efficacious Inhibitors of Poly(ADP-ribose) Polymerase (PARP) for the Treatment of Cancer